GlobalBio
GlobalBio Inc. is a Cambridge, MA-based contract research organization founded in 2014 that discovers, optimizes, and develops therapeutic antibodies using its proprietary ALTHEA Libraries™ phage-display platform, serving pharmaceutical companies, biotech firms, and academic institutions in Immuno-Oncology, Oncology, and Infectious Diseases.
- Company typePrivate
- Founded2014
- HeadquartersBrookline, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What GlobalBio does
GlobalBio Inc. is a privately held contract research organization founded in 2014 by Dr. Juan C. Almagro and headquartered at One Mifflin Place, Harvard Square, Cambridge, Massachusetts. The company focuses on the discovery, optimization, and development of therapeutic antibodies for Immuno-Oncology, Oncology, and Infectious Diseases, generating revenue through two mechanisms: (i) B2B contract research engagements that take client programs from antibody discovery through protein expression and GLP-compliant cell-based biological assays, and (ii) licensing of its proprietary ALTHEA Libraries™ human antibody phage-display technology to academic and biotech users. Pricing is not publicly disclosed and is structured on a per-project, custom-contract basis; direct enterprise field sales is the stated go-to-market motion.
The company's technology stack is anchored by its ALTHEA Gold Libraries™ and ALTHEA Gold Plus Libraries™, proprietary human antibody phage-display libraries engineered to maximize the probability of obtaining specific, high-affinity, and developable therapeutic antibodies. The integrated service offering covers the antibody development workflow: ALTHEA-based discovery, antibody design and engineering using advanced bioinformatics and computational modeling, recombinant protein expression and characterization, and GLP-compliant biological assays (ADCC, CDC, apoptosis) executed within a Quality Management System. Scientific credibility is established by Dr. Almagro's 30+ years of industry and academic experience — including senior positions at Pfizer (Sr. Director) and Johnson & Johnson (Scientific Director and Head of Antibody Design) — and an active publication record spanning mAbs, Frontiers in Immunology, Viruses, Cold Spring Harbor Protocols, and Nature Biotechnology through 2025.
GlobalBio operates with 11–50 employees from a single Cambridge, MA site and remains largely self-funded beyond a $172,987 seed grant from the National Science Foundation in December 2014; no institutional venture, growth equity, or strategic capital has been disclosed. Strategic commercial activity has expanded through 2024 partnerships — an extended collaboration with Antiverse to advance antibody cancer therapeutics and an arrangement with NeoChromosome to launch pre-transformed antibodies — indicating a modest shift from pure service delivery toward co-developed products and reagent catalog sales. Patent records cited in the company's profile reflect inventions in which Dr. Almagro appears as a co-inventor but assigned to third parties (Pfizer, Johnson & Johnson, Incyte, Eisai, Arch Oncology); there is no evidence that GlobalBio itself holds issued composition-of-matter IP on its libraries or pipelines.
GlobalBio firmographics
Firmographics- Name
- GlobalBio
- Legal name
- GlobalBio Inc.
- Website
- https://globalbioinc.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GlobalBio Inc. is a Cambridge, MA-based contract research organization founded in 2014 that discovers, optimizes, and develops therapeutic antibodies using its proprietary ALTHEA Libraries™ phage-display platform, serving pharmaceutical companies, biotech firms, and academic institutions in Immuno-Oncology, Oncology, and Infectious Diseases.
- Ownership category
- akta.pro rank
GlobalBio industry classification
Industry- Product category
- Contract Research Services (Therapeutic Antibody Discovery & Development)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Clinical Research & Trial Central Laboratories (HLAFAMAL), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where GlobalBio is headquartered
LocationHeadquarters
- HQ city
- Brookline
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GlobalBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Contract Research Services: GlobalBio signs and executes contracts to optimize and develop antibody-based therapeutics for pharmaceutical and biotech clients. Revenue is generated through service contracts for antibody discovery, optimization, and development services.
- ALTHEA Libraries Licensing: Licensing of proprietary human antibody libraries (ALTHEA Gold Libraries™) to academic and biotech companies for therapeutic antibody discovery.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
GlobalBio product offering
Product offeringCore offering
GlobalBio provides contract research services for the discovery, optimization, and development of therapeutic antibodies. Its core offering centers on proprietary ALTHEA Libraries™ human antibody phage display technology, complemented by antibody design and engineering, recombinant protein expression and characterization, and GLP-compliant biological assays. The company serves pharmaceutical, biotech, and academic clients working in Immuno-Oncology, Oncology, and Infectious Diseases.
Product overview
GlobalBio is a therapeutic antibody discovery and development company offering an integrated service portfolio centered around its proprietary ALTHEA Libraries™ phage display technology. The core offering consists of antibody libraries for discovery, complemented by four specialized services: Antibody Design & Engineering (using bioinformatics tools for protein engineering), Protein Expression & Characterization (recombinant protein production), and Biological Essays (GLP-compliant cell-based assays). Founded in 2014 and based in Cambridge, MA, the company focuses on Immuno-Oncology, Oncology, and Infectious Diseases therapeutic areas.
Differentiator
Problem solved
Functional benefit
Brands
- ALTHEA Libraries™: Human antibody libraries for therapeutic antibody discovery that maximize the probability of obtaining specific, high affinity and developable antibodies. Includes ALTHEA Gold Libraries™ and ALTHEA Gold Plus Libraries™.
Products and services
- ALTHEA Libraries™ Human antibody phage display libraries for therapeutic antibody discovery designed to maximize the probability of obtaining specific, high-affinity and developable antibodies. Used by academic institutions and biotech companies for therapeutic antibody discovery.
- Antibody Design & Engineering Protein design and engineering services using advanced bioinformatics tools and modeling to develop antibodies with characteristics needed for preclinical and clinical phases of pharmaceutical development. For pharmaceutical and biotech clients developing antibody-based therapies.
- Protein Expression & Characterization Comprehensive protein expression and purification services tailored to each client's protein and research project specifications, offered throughout diverse phases of biomedical research development. For pharmaceutical, biotech, and academic clients needing recombinant proteins.
- Biological Essays (Bioassays) GLP-compliant cell culture-based biological assays including ADCC, CDC, Apoptosis, and other audited bioassays conducted within a Quality Management System. For pharmaceutical and biotech clients requiring regulated preclinical characterization.
Quantifiable outcome
- ALTHEA Gold Libraries™ successfully used by several academic and biotech companies for therapeutic antibody discovery
Companies that use GlobalBio
Customer profileSegments3 records
Ideal customer profiles3 records
GlobalBio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
GlobalBio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- AntiversecoreGlobalBio and Antiverse have extended their collaboration to advance antibody cancer therapeutics. The partnership focuses on leveraging both companies' capabilities for antibody discovery and development in the oncology space.
- NeoChromosomeminorGlobalBio and NeoChromosome partnership for launch of pre-transformed antibodies, as referenced in Yahoo Finance news release.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
GlobalBio competitors and assessment
Company assessmentDirect peers
- AbCellera Biologics: Public antibody discovery company operating a single-cell screening and AI-enabled platform that discovers and engineers therapeutic antibodies for pharma partners — directly comparable to GlobalBio's phage display discovery and engineering service model.
- Adimab: Leading independent antibody discovery and engineering platform that licenses its discovery technology and provides full-service antibody optimization to pharma and biotech — the closest direct analog to GlobalBio's ALTHEA Libraries licensing plus engineering offering.
- Antiverse: AI-driven antibody design company and GlobalBio's named co-development partner, focused on computational antibody discovery for oncology and other indications — a directly comparable discovery-platform peer.
- Creative Biolabs: Specialist CRO offering custom antibody discovery, engineering, and characterization services using phage display and hybridoma platforms — closely comparable to GlobalBio's full service stack for pharma and academic clients.
Broad incumbents
- Twist Bioscience: Public synthetic biology platform that sells antibody libraries, discovery libraries, and biologics engineering services to pharma — overlapping with GlobalBio's library-based discovery and engineering value proposition at much larger scale.
- GenScript: Global life-science services company offering antibody discovery, protein expression, and bioassay services — directly overlapping GlobalBio's protein expression, antibody engineering, and bioassay service lines across a much larger footprint.
- Bio-Techne: Public life-science tools and reagents provider with a biologics and antibody reagents business serving pharma and academic researchers — adjacent competitor for antibody-related reagents and assay services used by GlobalBio's customer base.
- Lonza: Global biologics CDMO and CRO with large-scale antibody discovery, cell-line development, and bioassay capabilities — competes for the same large-pharma antibody outsourcing budget as GlobalBio, especially in preclinical services.
- Charles River Laboratories: Major CRO/CDMO with end-to-end biologics discovery, development, and safety assessment services — competes for integrated antibody discovery-to-preclinical contracts that GlobalBio targets.
Emerging players
- Distributed Bio (Charles River): Antibody engineering and library platform originally developed as an independent CRO and now part of Charles River, offering SuperHuman and other antibody libraries — a directly comparable library-plus-services platform peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
GlobalBio social profiles
Digital presenceGlobalBio compliance and trust
Trust signalCompliance1 record
GlobalBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
GlobalBio leadership team
Management profileNumber of profiles
Profiles1 record
GlobalBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GlobalBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GlobalBio
What does GlobalBio do?
GlobalBio provides contract research services for the discovery, optimization, and development of therapeutic antibodies. Its core offering centers on proprietary ALTHEA Libraries™ human antibody phage display technology, complemented by antibody design and engineering, recombinant protein expression and characterization, and GLP-compliant biological assays. The company serves pharmaceutical, biotech, and academic clients working in Immuno-Oncology, Oncology, and Infectious Diseases.
Is GlobalBio a public or private company?
GlobalBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was GlobalBio founded?
GlobalBio was founded in 2014. It employs 11 to 50 people.
Where is GlobalBio based?
GlobalBio is headquartered in Brookline, United States, in the North America region.
How does GlobalBio make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are ALTHEA Libraries Licensing.
Who are GlobalBio's main competitors?
Direct peers on record are AbCellera Biologics, Adimab, Antiverse and Creative Biolabs. Broad incumbents are Twist Bioscience, GenScript, Bio-Techne, Lonza and Charles River Laboratories. Distributed Bio (Charles River) is listed as an emerging player.
Does GlobalBio have an API?
No public API is recorded for GlobalBio.
What industry is GlobalBio in?
GlobalBio's product category is Contract Research Services (Therapeutic Antibody Discovery & Development). Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 541714 and its SIC code is 8731.